In Vitro Transcription Template Market Size, Share and Trends Analysis, By Product Type (Enzymes, Kits and Reagents, and Custom Synthesis), By Application, By Indication, By End-Use (Pharmaceutical & Biotechnology Companies, Academic & Research Institutions, Contract Research Organizations, and Others), and By Region, Forecast 2025-2032

In Vitro Transcription Template Market Overview and Key Insights:

The in vitro transcription template market size reached USD 293.7 million in 2024 and is expected to register a revenue CAGR of 20.5% during the forecast period. In vitro transcription is a relatively simple process that enables for template-directed synthesis of RNA molecules of any sequence from small oligonucleotides to multiple kilobases in μg to mg quantities. In vitro transcripts are utilized for analytical purposes, structural studies, biochemical and genetic research, and as functional molecules.

Market Drivers:

Rising demand for mRNA-based therapeutics is a key driver of revenue growth in the in vitro transcription template market. The therapeutic use of messenger RNA (mRNA) has raised high hopes for combating a wide spectrum of incurable disorders. Furthermore, in vitro transcribed mRNA has achieved planned production, which is more effective, faster to design and produce, adaptable, and cost-efficient than traditional procedures. Unlike DNA-based medications, mRNA transcripts have a relatively high transfection efficiency and low toxicity since they do not require entry into the nucleus to act.

Importantly, mRNA poses no risk of inadvertent infection or opportunistic insertional mutagenesis. Furthermore, mRNA offers a vast potential for treating disorders that need protein expression, as well as improved therapeutic efficacy, because it is continuously translated into encoded proteins/peptides, resulting in long-term expression as opposed to temporary typical protein/peptide therapies.

On November 2024, Synthego has expanded its solution portfolio with the addition of high-performance RNA enzymes, T7 RNA Polymerase and RNase Inhibitor, bolstering its ability to service the RNA research and therapeutic sectors. These recently released in vitro transcription (IVT) enzymes are specifically intended to address important issues in RNA synthesis and modification, and they supplement Synthego’s industry-leading gRNAs. The T7 RNA Polymerase catalyzes efficient RNA synthesis with high yield and purity, making it appropriate for mRNA therapies, gene editing platforms, and synthetic biology processes.

Market Opportunity:

Growth of the mRNA vaccine act as an opportunity for in vitro transcription template market. mRNA vaccines combine desirable immunological features with an excellent safety profile and the previously unmatched flexibility of genetic vaccinations. Based on in situ protein expression, mRNA vaccines can induce a balanced immune response that includes both cellular and humoral immunity while avoiding MHC haplotype restriction. Furthermore, mRNA is an intrinsically safe vector since it is a minimum and temporary carrier of information that has no interaction with the genome. Because any protein can be expressed from mRNA without changing the production process, mRNA vaccines provide the greatest degree of development flexibility.

On August 2025, Pfizer Inc. and BioNTech SE announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for their LP.8.1-adapted monovalent COVID-19 vaccine. The approval covers use in adults aged 65 and older, as well as individuals aged 5 to 64 with at least one underlying condition that increases the risk of severe COVID-19 outcomes. The application also included preclinical data demonstrating that the LP.8.1-adapted monovalent vaccine produces enhanced immune responses against several circulating SARS-CoV-2 sublineages—including XFG, NB.1.8.1, and other current variants—compared to their JN.1- and KP.2-adapted monovalent COVID-19 vaccines.

Recent Trends:

Emerging trends include novel enzymes and enzyme engineering, automation, and robotics in IVT, and AI and machine learning.

Artificial intelligence, machine learning, and computer vision therapies can improve several elements of human visual perception to identify relevant clinical patterns. AI/ML allows for speedier illness diagnosis and progression tracking by using pattern recognition and segmentation techniques to medical images. Translation is a process that converts mRNA into proteins. This mechanism is strictly controlled and plays an important role in the development of mRNA-based vaccines and therapies.

RNA design has been approached using a variety of methodologies, including adaptive random walk, stochastic local search, seeding heuristics, genetic algorithms, constraint programming, simulated annealing, and hierarchical decomposition. Predicting folding sequences based on energy models and designing base sequences to achieve specific secondary structures are time-intensive processes. These challenges can be effectively addressed by applying deep learning techniques, particularly reinforcement learning.

Restraints & Challenges:

Despite its advantages, IVT presents unique obstacles such as enzyme specificity and efficiency, cost considerations, process optimization, and maintaining the stability and shelf life of produced mRNA. Stability and shelf life continue to hamper the development and delivery of mRNA therapies, particularly when considering formulation, storage, and transportation alternatives.

A poor-quality DNA template could cause the in vitro transcription reaction to fail completely. DNA produced using standard miniprep techniques should be of adequate quality for in vitro transcription. However, impurities like ethanol or salts left behind from the DNA purification procedure can block the RNA polymerases.

Product Type Segment Insights and Analysis:

Based on the product type, the in vitro transcription template market is segmented into enzymes, kits and reagents, and custom synthesis.

Enzymes segment contributed the largest market share in 2024. Enzymes is further sub segmented into RNA polymerases, nucleases, ligases, and others. In vitro transcription enzymes are essential components that drive the enzymatic synthesis of RNA molecules from DNA templates in a regulated laboratory setting. Unlike biological transcription, IVT gives researchers complete control over the sequence, length, and alterations to the RNA generated. Researchers created mutant forms of the T7 RNA polymerase (T7 RNAP), which is routinely utilized in IVT, to minimize the creation of immunostimulatory contaminants during mRNA synthesis. This procedure involves assessing the mutant’s effect on impurity profiles, RNA yields, and the possibility of downstream purification.

On January 2025, Aldevron, a global leader in DNA, RNA, and protein creation, has introduced its most recent discovery, Alchemy cell-free DNA technology.  This groundbreaking method marks a huge step forward in synthetic DNA production, providing a cell-free, enzymatic approach for producing linear DNA (linDNA) templates for in vitro transcription (IVT) synthesis of mRNA molecules.  Alchemy cell-free DNA technology is now available in research grade, giving researchers a faster and more efficient way to create high-quality DNA templates.

Application Segment Insights and Analysis:

Based on the application, the in vitro transcription template market is segmented into mRNA therapeutics and vaccines, gene therapy and cell therapy, RNA research & functional studies, personalized medicine & oncology, diagnostics, and others.

mRNA therapeutics and vaccines segment contributed the largest market share in 2024. The ability of synthetic mRNA to mimic the function of mature mRNA has increased its potential for a variety of therapeutic applications. These therapies include in vivo mRNA administration for protein replacement, stem cell induction, and cancer immunotherapy. As a result, mRNA-based therapies have emerged as an appealing new therapeutic class, poised to transform cancer treatment via a variety of techniques, including therapeutic vaccinations, monoclonal antibodies, immunomodulatory medications, and chimeric antigen receptor (CAR) cell therapy.

The development and approval of mRNA vaccines for SARS-CoV-2 within one year of the start of the COVID-19 pandemic demonstrated the great potential of mRNA technology. With projected advances and correct biomaterial design, mRNA-based vaccines and medicines will virtually probably be in great demand for a wide range of clinical applications in the next years. Currently, over 190 businesses and institutes are working to create over 310 mRNA vaccines and treatments. The development of these drugs spans from discovery and preclinical investigations to various stages of clinical trials. There are 125 items in the clinical pipeline worldwide, with vaccines accounting for 65% and medicines for 35%.

On June 2023, Eurofins Genomics Blue Heron has announced the availability of cutting-edge IVT mRNA Synthesis Services. The new service provides a comprehensive option for researchers looking for high-quality, bespoke mRNA synthesis with quick turnaround times. The IVT mRNA Synthesis Service is based on cutting-edge in vitro transcription (IVT) technology, which enables the rapid and efficient synthesis of high-quality messenger RNA transcripts. The IVT mRNA Synthesis Service was created to satisfy the demands of scientists from a variety of disciplines, including molecular biology, drug discovery, vaccine development, and gene therapy.

Indication Segment Insights and Analysis:

Based on the indication, the In Vitro Transcription Template market is segmented into cancer, infectious disease, lifestyle disease, genetic disease, neurological disorders, and others.

Cancer segment contributed the largest market share in 2024. According to the American Cancer Society, in 2025, the US is projected to have nearly 2 million new cancer cases and 618,000 deaths, excluding non-melanoma skin cancers. In 2025, the US is expected to have 316,950 new cases of invasive breast cancer in women and 2,800 in men, as well as 59,080 cases of ductal carcinoma in situ (DCIS) in women. By 2025, cancer will affect approximately 9,550 children (ages 0-14) and 5,140 adolescents (ages 15-19), resulting in 1,050 children and 600 adolescents dying from the disease. Cancer is the biggest cause of death for children and adolescents.

On September 2024, TriLink BioTechnologies and Alphazyme, both part of Maravai LifeSciences, have teamed up to develop CleanScribe RNA Polymerase, a revolutionary enzyme that decreases double-stranded RNA (dsRNA) in mRNA generation. CleanScribe RNA Polymerase is a new DNA-dependent RNA polymerase that catalyzes the in vitro transcription (IVT) of a recombinant gene controlled by the T7 promoter. CleanScribe RNA Polymerase offers researchers a straightforward technique to dramatically reduce dsRNA in their IVT while maintaining other critical mRNA quality properties.

Geographical Outlook:

In vitro transcription template market is strategically segmented by geography to provide a comprehensive understanding of regional market dynamic. Discover demand analysis, emerging trends, and growth opportunities shaping market performance across different region and countries.

North America In Vitro Transcription Template Market:

North America is registered to have highest market share in in vitro transcription template market in 2024. This is mainly driven by rising prevalence of chronic disorders and rising demand for mRNA-based therapeutics. According to the American Lung Association, cystic fibrosis affects around 40,000 persons in the United States and an estimated 100,000 people worldwide. Approximately one in every thirty people in the United States is a carrier. CF is most frequent in white people; however, it can affect people of many colors and ethnicities, occasionally resulting in a delayed diagnosis.

On January 2025, Nature’s Toolbox (NTx), a life sciences company that develops next-generation platforms for RNA and protein manufacturing, has announced the full commercial availability of NTxscribe, a benchtop continuous flow RNA in vitro transcription (IVT) and purification system that brings cost-effective and scalable RNA manufacturing to market. NTxscribe generates 10-50 mg of high integrity RNA in two hours, reducing the time required to bring innovative medicines and vaccines to market and empowering researchers, biotech, and pharmaceutical firms to make customized medicine a reality.

Moreover, on May 2024, GenScript Biotech Corporation, a global leader in life science research tools and services, announced that its in vitro transcription (IVT) RNA synthesis portfolio will now feature self-amplifying RNA (saRNA). This cutting-edge addition strengthens GenScript’s position at the vanguard of IVT RNA technology, providing a new and innovative format for researchers working on vaccines, cancer immunotherapy, and gene or cell therapy development.

Asia Pacific In Vitro Transcription Template Market:

Asia Pacific is expected to register the fastest growth rate during the forecasted period, driven by rising demand for mRNA-Based therapeutics, technological innovations in DNA synthesis, template design, and purification processes, and. Furthermore, increase in expenditures of healthcare sector is also driving the market growth in the region. On March 2024, Takara Bio has introduced PrimeCap T7 RNA Polymerase, a mutant T7 RNA polymerase that is ideal for mRNA therapeutic research and development. mRNA vaccines have shown successful as a protection against the coronavirus, with ongoing research expanding beyond infectious illness prevention to medicinal applications such as cancer treatment.

Europe In Vitro Transcription Template Market:

Europe is expected to have considerable market share in 2024. According to the UK BioIndustry Association (BIA), the industry raised over GBP 3.5 billion (USD 4.36 million), representing a 94% increase from 2023. From pioneering early-stage research to developing innovative cures, UK life science businesses are tackling some of the world’s most pressing health issues. Furthermore, on June 2025, the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) is establishing 18 new Research Training Groups (RTGs) to strengthen the support provided to researchers in their early careers. The new RTGs will get around Euro 130 million during the first five years. This includes a 22% buffer for indirect project costs. The new RTGs include four International Research Training Groups (IRTGs) with partners from the United States, Italy, Canada, and France.

Competition Analysis:

The in vitro transcription template market is characterized by a fragmented structure, with several players competing across various segments and regions. list of major players included in the in vitro transcription template market report are:

• Takara Bio Inc
• Bio-Synthesis Inc
• Integrated DNA Technologies, Inc.
• TriLink BioTechnologies
• Promega Corporation
• GenScript Biotech Corporation
• New England Biolabs
• Amsbio
• Thermo Fisher Scientific Inc.
• Synthego Holdings LLC
• OZ Biosciences
• GeneCopoeia, Inc.
• Creative Biolabs
• GeneBio Systems
• Hoffmann-La Roche Ltd 

Strategic Developments in In Vitro Transcription Template Market:

• In May 2025, TriLink BioTechnologies, a Maravai LifeSciences company, began with a large donation to leading academic laboratories in the United States and Europe. The donation marks the release of TriLink’s first mRNA synthesis kit with CleanCap capping technology, an all-in-one kit that includes breakthrough goods in a single box at a reasonable price. Seven academic institutions will each get ten kits capable of producing up to 250mg of capped mRNAs, facilitating and stimulating future research and development in the field of mRNA-based medicine.
• In March 2025, Primrose Bio, Inc., a company that develops proprietary therapeutic manufacturing technologies, has announced the release of Prima RNApols ExTend, a RNA polymerase designed to significantly improve the manufacturing of long-template mRNA vaccines and therapeutics, including mRNA medicines based on self-amplifying mRNA. Prima ExTend beats typical T7 polymerase by producing higher-quality mRNA with less dsRNA, overcoming a common mRNA manufacturing issue and improving downstream purifying efficiency.

Key Advantages for Stakeholders:

Navistrat Analytics’ industry report provides an in-depth quantitative analysis of various market segments, historical and current trends, market forecasts, and dynamics within the global market. The historical years covered in this report are 2022 to 2023, with 2024 serving as the base year for market size calculations. The forecast period extends from 2025 to 2032.

The report includes an executive summary and a comprehensive overview of market drivers, restraints, opportunities, and challenges (DROC), along with insights into regulatory standards. It features detailed analyses such as PORTER’s Five Forces, SWOT, and PESTLE, as well as assessments of technological trends and the competitive landscape.

PORTER’s Five Forces analysis helps stakeholders evaluate the impact of new entrants, competitive rivalry, supplier power, buyer power, and substitution threats, enabling them to assess the level of competition and the attractiveness of the global market. The competitive landscape provides stakeholders with a clear understanding of the current market positions of key players, offering valuable insights into their competitive environment.

Scope And Key Highlights Of The In Vitro Transcription Template Market Report:

The In Vitro Transcription Template market report offers a detailed analysis of market size, including historical revenue (in USD Million) data for 2022-2023 and revenue forecasts for 2025-2032 across the following segments:

• Product Type Outlook (Revenue, USD Million; 2022-2032)
  • Enzymes
    • RNA polymerases
    • Nucleases
    • Ligases
    • Others
  • Kits and Reagents
    • IVT kits
    • Purification kits
    • Labeling kits
  • Custom Synthesis
    • Custom RNA synthesis
    • Modified RNA synthesis

• Application Outlook (Revenue, USD Million; 2022-2032)
  • mRNA Therapeutics and Vaccines
  • Gene Therapy and Cell Therapy
  • RNA Research & Functional Studies
  • Personalized Medicine & Oncology
  • Diagnostics
  • Others

• Indication Outlook (Revenue, USD Million; 2022-2032)
  • Cancer
  • Infectious Disease
  • Lifestyle Disease
  • Genetic Disease
  • Neurological Disorders
  • Others

• End-Use Outlook (Revenue, USD Million; 2022-2032)
  • Pharmaceutical & Biotechnology Companies
  • Academic & Research Institutions
  • Contract Research Organizations (CROs)
  • Others

• Regional Outlook (Revenue, USD Million; 2022-2032)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • U.K.
    • Italy
    • Spain
    • Benelux
    • Nordic Countries
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Oceania
    • ASEAN Countries
    • Rest of APAC
  • Latin America
    • Brazil
    • Rest of LATAM
  • Middle East & Africa
    • GCC Countries
    • South Africa
    • Israel
    • Turkey
    • Rest of MEA

Frequently Asked Questions (FAQ) about the In Vitro Transcription Template market report